IS IT POSSIBLE TO REDUCE DEATHS AMONG PEOPLE ON ANTI-HIV TREATMENT?

EXECUTIVE SUMMARY

In 2017, the death rate among the general population in India was 6.4, in Maharashtra it was 5.9 and in contrast, among PLHIV in Maharashtra it was 83, much higher.

In order to understand and act on the factors associated with mortality among People Living with HIV (PLHIV) accessing Antiretroviral therapy (ART) services, the HIV programme in Maharashtra analysed 61113 PLHIV older than 15 years, registered and on anti-HIV treatment at 73 ART centres in Maharashtra (excluding Mumbai) during the calendar years 2015-17.

The analysis found that patients should be encouraged to be tested early for HIV, and those who test positive should be encouraged to initiate early treatment. Major efforts are required not only to trace those who are lost to follow-up but to initiate mechanisms to trace these patients early, when they have missed their monthly dose of treatment.

Effective implementation of test and treat with proper monitoring of patients in the first three months of treatment will reduce the mortality and will increase the survival among PLHIV.

THE ISSUE

In 2017, the death rate among the general population in India was 6.4, in Maharashtra it was 5.9 and in contrast, among PLHIV in Maharashtra it was 83, much higher.

Considering mortality is amenable to health care, as informed by the global and Indian literatures, the HIV programme in Maharashtra wanted to understand and act on the factors associated with death among PLHIV accessing ART services. The factors that needed to be explored included gender, age, immunological status and duration on ART.

Effective implementation of test and treat with proper monitoring of patients in the first three months of treatment will reduce the mortality and will increase the survival among PLHIV.

1Maharashtra State AIDS Control Society, Mumbai | 2National AIDS Control Organisation, New Delhi | 3Former Programme Officer, NACO, New Delhi
THE STUDY

- To identify the factors associated with death among PLHIV accessing anti-HIV treatment in ART centres of Maharashtra, India.
- To inform the programme managers on the importance of intervening at the first three months of ART initiation in reducing the death among PLHIV on anti-HIV treatment in Maharashtra, India.

Only PLHIV age > 15 yrs were considered for analysis, as there is a difference in blood count (CD4 level) between children and adult for ART initiation.

THE METHODOLOGY

- Data about 61113 PLHIV registered and on anti-HIV treatment at 73 ART centres in Maharashtra (excluding Mumbai), during the calendar years 2015-17, was analysed.
- The end point of follow-up of those registered was July 2018.
- PLHIV Transferred-out and without date of ART initiation, were not considered for this analysis.
- Mortality density (per thousand months) was calculated.
- Factors associated with death were explored.
- Regional data was analyzed.

Map on the regional-wise representation of 73 ART centres at Maharashtra
## Characteristics

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>N</th>
<th>Khandesh (9226)</th>
<th>Konkan (8967)</th>
<th>Marathwada (8749)</th>
<th>Vidarbha (12586)</th>
<th>Western (21585)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>26932</td>
<td>10%</td>
<td>11%</td>
<td>10%</td>
<td>11%</td>
<td>9%</td>
</tr>
<tr>
<td>Male</td>
<td>31952</td>
<td>17%</td>
<td>17%</td>
<td>17%</td>
<td>17%</td>
<td>14%</td>
</tr>
<tr>
<td>Age group</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;45 yrs</td>
<td>54322</td>
<td>13%</td>
<td>13%</td>
<td>12%</td>
<td>12%</td>
<td>10%</td>
</tr>
<tr>
<td>&gt;=45 yrs</td>
<td>6791</td>
<td>25%</td>
<td>24%</td>
<td>23%</td>
<td>24%</td>
<td>18%</td>
</tr>
<tr>
<td>Baseline CD4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BCD4 &gt; = 100</td>
<td>13143</td>
<td>9%</td>
<td>9%</td>
<td>9%</td>
<td>9%</td>
<td>7%</td>
</tr>
<tr>
<td>BCD4 &lt; 100</td>
<td>46142</td>
<td>29%</td>
<td>29%</td>
<td>29%</td>
<td>29%</td>
<td>25%</td>
</tr>
</tbody>
</table>

### FINDINGS

- Half of the 7875 deaths reported, occurred within the first three months of ART initiation.
- Death rate is higher among:
  - Males as compared to females
  - Elderly patients (more than 45 years) as compared to younger ones (less than 45 yrs)
  - Those with white blood cell count (CD4) less than 100, during registration.

### RECOMMENDATIONS

- Increase attention in the first 3 months of anti-HIV treatment initiation
- Provide close follow-up to male patients
- Provide additional care for elderly (above 45 years) PLHIV on anti-HIV treatment
- Ring the alarm among health care providers for patients presenting themselves late with lower blood cell count
- Develop a statewide strategy as no regional variation was observed

---

Half of the **7875 deaths** reported, occurred within the **first three months** of ART initiation.
ACKNOWLEDGEMENT

The study was undertaken as part of National Data Analysis Plan, Round II, initiated by NACO in 2018. We thank NACO and particularly, Strategic Information Division (Data Analysis & Use) for providing support to the study. We also thank our mentors, Dr Arvind Pandey and Dr Samiran Panda for guiding us in the development of the technical brief. We would also like to acknowledge the support of development partners – UNAIDS, CDC, WHO, USAID, LINKAGES, FHI 360, ACCELERATE and JHU – in finalising the technical briefs. Printing was supported by UNAIDS using the Cooperative Agreement Number NU2GGH001971-01-00 funded by the CDC.

Note: For any information on the study, kindly contact Dr Pramod Deoraj, Joint Director, CST, Maharashtra State AIDS Control Society at dnrtwi@gmail.com and/or Ms Vinita Verma, Programme Officer (Evaluation & Operational Research), National AIDS Control Organisation at vinitaverma.naco@gmail.com